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Summary Objective: To study the effect of medroxyprogesterone acetate (MPA) on
autonomic cardiac control in respiratory insufficiency in postmenopausal women.
Design: A prospective, single-blind study.
Subjects: Eighteen postmenopausal women with respiratory insufficiency and eight
asymptomatic postmenopausal women with nocturnal hypoxaemia as controls.
Methods: Oral MPA treatment was given at 30mg twice daily for 2 weeks. All-night
polysomnography including a two-channel electroencephalogram, an electro-oculo-
gram, an electromyogram, an electrocardiogram, arterial oxyhaemoglobin satura-
tion, maximum end-tidal CO2 partial pressure, a ballistocardiogram and breathing
movements were recorded at baseline and at the end of MPA treatment. Heart rate
variability (HRV) was calculated in time and frequency domains during various sleep
stages on and off MPA, and the results were correlated to respiratory variables.
Results: At baseline, patients had higher heart rate and lower HRV than controls,
suggesting increased cardiac sympathetic output. MPA increased HRV in patients, but
not in controls. End-tidal CO2 partial pressure decreased, and respiratory rate
increased during treatment in both groups.
Conclusions: HRV is compromised in women with respiratory insufficiency. Peroral
MPA increases their HRV to levels comparable with those in controls. This suggests an
improvement in vagal cardiac control beneficial to cardiovascular health.
& 2003 Elsevier Ltd. All rights reserved.
Introduction
Heart rate variability (HRV) is a measure of
autonomic neural influences on the heart. In a
healthy man, heart rate fluctuates constantly, and
resting HRV is mainly under vagal control. Stress
increases the relative influence of the sympathetic
nervous system on the heart, thus decreasing HRV.1
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Reduced HRV increases the susceptibility for ven-
tricular tachyarrhythmias and sudden cardiac death
in the general population.1–3 HRV has been ob-
served to be reduced in patients with respiratory
insufficiency, and this reduction correlates strongly
with the severity of the respiratory condition
assessed with forced expiratory volume.4,5 Con-
sidering the effects of HRV on cardiovascular
prognosis, this leads to an assumption of a major
role of HRV in the increase of cardiac events
observed in nocturnal respiratory disturbance
states.6
It has been suggested that oestrogen has a
positive effect on cardiac autonomic modulation,
thereby improving cardiac health.7 An increase in
HRV is due to enhanced vagal activity, which is
antifibrillatory and thus cardioprotective.8 Proges-
tins are needed in oestrogen replacement therapy
to protect the uterine endometrium.9 Progestins,
like medroxyprogesterone acetate (MPA), are re-
spiratory stimulants,10 although this effect requires
higher dosage than in postmenopausal hormone
replacement therapy. Therefore, progestins correct
the abnormal balance of the arterial blood gases in
respiratory insufficiency.11 On the other hand, the
exact influence of progestins on autonomic control
of the heart is not known. Recent studies, however,
have suggested that combined HRT reduces HRV,
thus possibly having negative effects on cardiovas-
cular health, while unopposed oestrogen does not
change HRV.12,13
In order to evaluate whether MPA impairs the
autonomic control of the heart, we decided to
investigate the effect of plain MPA on cardiac
autonomic control in a group of postmenopausal
women with respiratory insufficiency and in a
control group of asymptomatic postmenopausal
women with partial upper airway obstruction-
related nocturnal hypoxia.
Subjects and methods
In this study, sleep data with simultaneous all-night
high-resolution electrocardiogram (ECG) recordings
were used. Some of these data have also been used
in an earlier study on the effect of MPA on sleep and
breathing.14
Eighteen postmenopausal women with stable-
phase permanent or episodic hypercapnic or hy-
poxaemic respiratory insufficiency participated in
the study. The respiratory insufficiency was caused
by COPD (12 cases), end-stage asthma (three
cases), or late sequelae of pulmonary tuberculosis
(four cases). The patients had moderate to severe
ventilatory impairment according to pulmonary
function tests. At baseline, their mean FEV1 (SD)
was 0.91 (0.47) l or 36 (18)%, mean FVC 1.50 (0.65) l
or 50 (19)%, FEV% 64 (18)% of predicted, mean
arterial pH 7.40 (0.03), PaCO2 5.6 (0.4) kPa, and
PaO2 9.6 (1.1) kPa. They were selected from
hospital patient records, and these 18 fulfilled
inclusion criteria in a telephone and personal
interview, passed a clinical examination and vo-
lunteered. These participants were required to be
over 50 years of age and they had been post-
menopausal for at least 2 years.
Eight postmenopausal hysterectomised women
served as control group. These women were
selected from a group of 71 postmenopausal
women with no respiratory symptoms or previously
diagnosed diseases.15 The controls were asympto-
matic and had normal flow-volume spirometry
values, but had presented with partial upper airway
obstruction-related nocturnal hypoxaemia during a
previous sleep recording, and thus were supposed
to benefit from high-dose MPA therapy. Their mean
FEV1 was 2.53 (0.30) l or 98 (8)%, mean FVC 2.91
(0.39) l or 91 (9)%, and FEV% 87 (5)% of predicted.
The controls were thus selected to avoid the
possible side effects of high-dose progestins in
completely healthy postmenopausal women. Their
mean arterial pH was 7.41 (0.01), PaCO2 5.4
(0.3) kPa, and PaO2 10.8 (1.7) kPa.
Exclusion criteria included major systemic dis-
ease, alcohol or drug abuse or current smoking,
long-term oxygen therapy and contraindications to
progestin therapy. One participant in the control
group and one in the patient group used unopposed
oestrogen replacement therapy. Beta blockers were
used by two controls and one patient, diuretics by
one control and five patients, calcium channel
blockers by two patients, nitrates by five patients,
and digoxin by one patient. Fifteen patients used
inhaled and three oral corticosteroids, 12 antic-
holinergic drugs and 15 b2 agonists.
The study design is shown in Fig. 1. Seven days
after the baseline measurements, a 2-week oral
progestin therapy was started in the asymptomatic
controls. 30mg of MPA (Lutopolar, Orion Pharma,
Espoo, Finland) was administered 2 h before going
to bed and 30mg at bedtime. The participants with
respiratory insufficiency were given a 2-week
placebo treatment beginning 7 days after baseline,
but this regimen was not included in this analysis.
The 2-week MPA regimen was started 7 days after
the placebo treatment. Originally, we intended to
make a double-blind, crossover study, but a pilot
study in the controls showed that the respiratory
effects of MPA had a carry-over effect of over 3
weeks. As exacerbations of the patients’ pulmonary
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disease could have devastated a crossover study
with a lengthy washout period, we decided, for the
patients’ safety, to opt for a single-blind design
where placebo was administered before MPA.
The sleep data consisted of a whole-night
polysomnography including a two-channel electro-
encephalography, electro-oculography, ECG, sub-
mandibular electromyography, arterial
oxyhaemoglobin saturation measured with a finger
probe pulse oximeter (Biox Ohmeda 3700e, BOC
Company, Louisville, Colorado), and end-tidal
carbon dioxide partial pressure measurement
(end-tidal PCO2) (Datex Normocap CO2 and O2
Monitor, Instrumentarium, Finland). With end-tidal
PCO2 we wished to gain an estimation of arterial
PCO2, and our estimates agree with our previous
finding on blood gas analyses in patients with
respiratory insufficiency.16 Breathing movements
and a ballistocardiogram were recorded with a
static charge sensitive bed (Biomatt, Biorec, Turku,
Finland).17 Sleep recordings were obtained at
baseline and at the end of the MPA treatment.
HRV was analysed from 3 to 6-min periods of
stage 2, slow wave sleep (combined stages 3 and 4),
and rapid eye movement sleep, each at the first
appearance. Periods of the awake state were not
sampled due to a high amount of movement
artifact. The sleep stages during these 3–6-min
periods were scored in 30-s epochs according to
standard criteria.18 Stage 2 and slow wave sleep
periods were classified as quiet sleep. The epochs
were carefully chosen not to include body move-
ments or extrasystolia. Respiratory rate was calcu-
lated from the respiratory signal of the static
charge sensitive bed to evaluate its possible effect
on HRV. Mean arterial oxyhaemoglobin saturation
and maximum end-tidal PCO2 were also calculated
from each analysed period.
HRV was assessed in both time and frequency
domain. In time domain, we calculated standard
deviation of the interbeat interval (SDNN), root
mean square of successive interbeat interval
differences (RMSSD), its coefficient of variance
(CVS) and the percentage of successive interbeat
intervals with over 50ms differences in duration
(pNN50). SDNN reflects overall HRV, and estimates
overall parasympathetic tone.1 RMSSD and pNN50,
although they are the products of different
mathematical formulae, are closely intercorrelated
and measure the beat-to-beat variation in heart
rate that is under the control of rapid variations in
vagal outflow.1 CVS indicates the ratio of RMSSD to
mean heart rate in per cent, extracting the effect
of changing heart rate from the obtained informa-
tion.19
In frequency domain, HRV was assessed using
power spectral analysis based on the Fast Fourier
transformation algorithm. Trends were removed
from the signal by subtracting the regression line.
The signal was resampled at a sampling frequency
of 4Hz, using linear interpolation, and windowed
using the Hanning window function. The Fast
Fourier transformation analysed spectra were sub-
jected to triangular smoothing, with a range of
0.01 Hz. We calculated total power (0 Hz to either
0.50 Hz or half the mean interbeat interval), which
is closely correlated to SDNN.1 The calculated sub-
bands were very low frequency power (0–0.04Hz),
low-frequency power (0.04–0.15Hz), and high-
frequency power (0.15–0.40Hz). The very low
frequency band is regulated by parasympathetic
oscillation and modulated by the renin–angioten-
sin–aldosterone system.20 The baroreflex-related
low-frequency band is modulated by both sympa-
thetic and parasympathetic nervous systems.21,22
The high-frequency oscillations represent respira-
tory variation, and they are closely correlated to
RMSSD and pNN50.21 The low-to-high-frequency
ratio was calculated for assessment of the sym-
pathovagal balance.23
Ethics
The study was approved by the Joint Committee on
Ethics of the University of Turku and Turku
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Figure 1 The study design.
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University Central Hospital. All subjects gave their
written informed consent after receiving oral and
written information.
Statistical analysis
Group differences were calculated at baseline and
during MPA treatment, as well as from the MPA
treatment effect by the Wilcoxon two-sample test
with the t distribution approximation (SAS software
release 8.1, SAS Institution Inc., Cary, NC). The
sleep-stage-induced differences in measured vari-
ables were similarly calculated at baseline, during
MPA treatment, and from the treatment-induced
difference. For interactions between sleep stage
and patient group, a repeated measures analysis of
variance with two factors was conducted. Skewed
distributions were corrected using logarithmic,
third root (pNN50), or 16th power (mean SaO2)
transformation. A P value of o0.05 was considered
statistically significant. Values are given as median
(range).
Results
One patient from the respiratory insufficiency
group withdrew from the study after her baseline
night, and another had to be excluded because of
acute aggravation of her chronic obstructive
pulmonary disease. One woman in the control
group had to be excluded because of frequent
extrasystolia. The ultimate size of the study group
was thus 23 women, of whom 16 had respiratory
insufficiency and seven were controls.
The median heart rate was higher in patients
with respiratory insufficiency than in controls (70
(56–100) bpm versus 61 (51–76) bpm, Po0:0001)).
All HRV variables were reduced in women with
respiratory insufficiency, except the low-to-high-
frequency ratio, which was similar to controls
(Table 1, Fig. 2).
The effect of MPA was highly different between
groups. During MPA treatment, a difference in heart
rate between groups was still observed (74 (52–
113) bpm versus 65 (57–83) bpm, P ¼ 0:018). In
patients with respiratory insufficiency, MPA did
not change mean heart rate, but it increased the
total power of HRV. The separate power bands,
however, were not affected. MPA also increased
RMSSD, CVS, and pNN50. In the control group, MPA
increased mean heart rate and decreased RMSSD
slightly, but had no other effects on HRV (Table 1,
Fig. 2).
Respiratory rate was higher and end-tidal PCO2
lower in women with respiratory insufficiency than
in controls. MPA increased respiratory rate and
median arterial oxyhaemoglobin saturation in both
groups. The increase in arterial oxyhaemoglobin
saturation on MPA was inversely proportional to
the baseline value (r ¼ 0:84). MPA reduced end-
tidal PCO2 in a similar way in both groups (3.5
(14.6–6.2)mmHg in respiratory insufficiency pa-
tients versus 5.9 (11.6–0.1)mmHg in controls,
P ¼ 0:07) (Table 2).
Sleep stage had no effect on time domain HRV. In
frequency domain, there were differences between
quiet and rapid eye movement sleep in the very
low- and high-frequency domains (Fig. 2). There
were no group differences in the sleep stage-
influenced pattern of HRV.
Sleep stage did not affect heart rate in patients
with respiratory insufficiency. However, heart rate
changed with sleep stage in controls (P ¼ 0:008 for
interaction between group and sleep stage effects
at baseline and P ¼ 0:017 on MPA). At baseline,
sleep stage did not affect respiratory rate in
patients with respiratory insufficiency, but in the
control group, respiratory rate was lower in quiet
than in rapid eye movement sleep (P ¼ 0:029). On
MPA, respiratory rate decreased in rapid eye
movement sleep compared to quiet sleep in
patients, while it remained unchanged in controls
(P ¼ 0:011). Median arterial oxyhaemoglobin sa-
turation was markedly lower in patients than in
controls in stage 2 sleep on MPA, while in the other
sleep stages, there was no marked difference
(P ¼ 0:047). The difference in pNN50 between
quiet and rapid eye movement sleep was smaller
in patients than in controls on MPA (P ¼ 0:05).
Discussion
The present study shows that MPA affects HRV in
postmenopausal women. MPA improved the dis-
turbed cardiac autonomic regulation observed in
those with severe respiratory insufficiency. In
asymptomatic controls, MPA administration only
increased heart rate, having neither positive nor
negative effects on HRV.
HRV was severely compromised in patients with
respiratory insufficiency. This is in line with
previous studies that show markedly reduced HRV
in several conditions affecting gas exchange, e.g.
asthma, chronic obstructive pulmonary disease,
and obstructive sleep apnea syndrome.4,5,24 This
reduction is probably secondary to the underlying
disorder. The patients are likely to benefit from the
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Table 1 Group effect and MPA versus baseline effect on time domain variables of heart rate variability.
Baseline Medroxyprogesterone acetate MPA effect
Stage 2 Slow wave sleep REM sleep Stage 2 Slow wave sleep REM sleep
Mean interbeat interval (ms)
Respiratory insuff. 860 (599;1066) 866 (742;1055) 861 (729;985) 804 (540;1151) 880 (705;1126) 775 (532;992) Ns
Controls 996 (945;1183) 993 (899;1105) 949 (796;1040) 998 (946;1050) 922 (777;996) 897 (722;936) o0.001
Group effect o0.001 0.018 0.006
SDNN (ms)
Respiratory insuff. 27 (5;119) 21 (10;90) 28 (14;87) 36 (5;132) 35 (9;148) 37 (6;121) Ns
Controls 42 (29;151) 35 (14;161) 42 (26;139) 37 (23;62) 28 (15;68) 44 (23;48) Ns
Group effect 0.007 Ns Ns
RMSSD
Respiratory insuff. 26 (4;140) 32 (7;89) 16 (5;138) 35 (4;152) 29 (8;184) 18 (6;139) 0.043
Controls 48 (27;249) 38 (13;276) 25 (13;231) 35 (16;67) 31 (11;51) 19 (8;32) 0.026
Group effect 0.020 Ns 0.017
CVS
Respiratory insuff. 3.1 (0.7;16.4) 3.2 (0.8;12.0) 1.7 (0.7;18.9) 3.4 (0.7;20.2) 3.2 (1.1;24.0) 1.9 (0.9;19.6) 0.026
Controls 4.0 (2.7;23.0) 3.4 (1.5;27.2) 3.2 (1.5;23.8) 3.7 (1.6;6.6) 3.4 (1.4;5.5) 2.1 (1.1;3.7) Ns
Group effect 0.035 Ns Ns
pNN50(%)
Respiratory insuff 2 (0;48) 1 (0;59) 0 (0;28) 11 (0;45) 8 (0;52) 1 (0;40) 0.034
Controls 32 (2;57) 20 (0;61) 1 (0;40) 12 (0;39) 10 (0;38) 0 (0;12) Ns
Group effect 0.013 Ns 0.013
Significances in italics indicate difference in MPA effect between groups. Sleep stages are pooled together. SDNN¼ standard deviation of the interbeat interval, RMSSD¼ root mean
square of successive interbeat interval differences, CVS¼ coefficient of variance for RMSSD, pNN50¼percentage of successive interbeat intervals with more than 50ms difference in
duration, respiratory insuff.¼ respiratory insufficiency, REM sleep¼ rapid eye movement sleep, MPA¼medroxyprogesterone acetate.
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improvement of cardiac autonomic regulation as
measured with HRV, because it has been shown that
overall and cardiovascular mortality risks are
reduced with increasing HRV.2,3
MPA increased heart rate in the control group,
which is supported by a previous study on the
effects of combined HRT in healthy women.12 In
contrast, however, although natural progesterone
changes autonomic cardiac control, the mean heart
rate and blood pressure are not affected by the
menstrual cycle.25
We found that in postmenopausal women MPA
increased respiratory rate and decreased end-tidal
PCO2. This is in line with a previous study, where
combined oestrogen and progesterone administra-
tion decreased end-tidal PCO2, and increased
carotid body neural response and hypoxic ventila-
tory responsiveness in cats.26 MPA enhances minute
ventilation, as well as the hypoxic and hypercapnic
ventilatory responses.10 The chronic CO2 retention
in chronic obstructive pulmonary disease is cor-
rected by MPA.11 In this study, MPA increased
arterial oxyhaemoglobin saturation in those pa-
tients with the most severe nocturnal hypoxaemia.
MPA administration is known to increase arterial
oxygen partial pressure (PO2),
27 which is reflected
in an increase of arterial oxyhaemoglobin satura-
tion. However, on the oxygen–haemoglobin disso-
ciation curve, even fairly strong increases in
arterial PO2 do not markedly change an arterial
oxyhaemoglobin saturation that is above 90%. A PO2
increase of a similar magnitude significantly in-
creases an arterial oxyhaemoglobin saturation that
is below 85%. This may explain why the median
arterial oxyhaemoglobin saturation did not change
even though lower saturations were clearly im-
proved.
In rats, hypoxia only influences HRV when
combined with changes in PCO2, whereas isocapnic
hypoxia does not change HRV.28 Furthermore,
supplemental oxygen does not decrease the num-
ber of nocturnal hypoxic arousals in chronic
obstructive pulmonary disease.29 In a subgroup of
patients with chronic obstructive pulmonary dis-
ease, long-term oxygen therapy increases arterial
CO2 partial pressure.
30 The increase in end-tidal
PCO2 and an increase in circulating CO2 have been
shown to centrally modulate sympathetic pregan-
glionic output.31,32 Based on these findings, we
hypothesise that hypercapnia, but not hypoxia,
is responsible for the changes in HRV. The effect
of MPA on HRV in patients with respiratory
insufficiency may also be affected by improved
respiration.
Most of our patients with respiratory insuffi-
ciency regularly used inhaled and systemic corti-
costeroids and sympathomimetics, medications
that undoubtedly affect autonomic nervous func-
tion. However, oral prednisone, which decreases
plasma noradrenaline concentrations and muscle
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Figure 2 Medians of frequency domain variables (milliseconds squared) in patients and controls at baseline (left
panels) and on MPA (right panels). (*) Significant difference between groups at Po0:05; (**) significant difference
between groups at Po0:01: The effect of MPA differed between groups in very low frequency power (P ¼ 0:038) and in
high-frequency power (P ¼ 0:005). The increase in total power in patients on MPA was statistically significant at
P ¼ 0:044: In very low frequency and high-frequency powers, there was a significant difference between quiet and rapid
eye movement sleep both at baseline and on MPA at Po0:05: S2¼ stage 2 sleep, SWS¼ slow wave sleep, REM¼ rapid eye
movement sleep.
MPA and heart rate variability 131
nerve sympathetic activity, has no effect on heart
rate and blood pressure in a group of 15 healthy
volunteers (12 men and three women).33 Moreover,
an acute inhalation of nebulisator doses of salbu-
tamol does not have an effect on HRV in patients
with chronic obstructive pulmonary disease,34
although in healthy subjects b2 agonists decrease
HRV and increase heart rate.35 Therefore, the
medication used by our patients with respiratory
insufficiency is unlikely to explain the group
differences. While the medication remained con-
stant throughout the study, it is not likely to have
influenced the MPA effect.
In both respiratory insufficiency patients and
controls, the effect of sleep stage on HRV was
similar to that observed in our previous study in
healthy postmenopausal women.13 This suggests
that women with severe hypoxaemic disorders,
although their cardiac autonomic control is other-
wise compromised, have normal sleep stage-
related patterns of HRV change.
We conclude that high-dose oral MPA has an
impact on cardiac autonomic regulation. The MPA
effect on HRV seems to depend on the severity of
the underlying respiratory condition. In subjects
with chronic respiratory insufficiency, the HRV
changes suggest a beneficial effect of MPA on
cardiovascular regulation. In asymptomatic wo-
men, although hypoxaemic during sleep, no nega-
tive impact of high-dose MPA on HRV can be
detected.
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